Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,822
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,571.40 | 40.30 | -0.47% |
CAC 40 | 7,864.44 | 46.05 | -0.58% |
DAX 40 | 23,999.17 | 123.23 | -0.51% |
Dow JONES (US) | 41,859.03 | 1.41 | -0.00% |
FTSE 100 | 8,739.26 | 47.20 | -0.54% |
HKSE | 23,544.31 | 283.47 | -1.19% |
NASDAQ | 18,953.39 | 80.74 | 0.43% |
Nikkei 225 | 36,985.87 | 313.11 | -0.84% |
NZX 50 Index | 12,662.25 | 40.85 | -0.32% |
S&P 500 | 5,843.75 | 0.86 | -0.01% |
S&P/ASX 200 | 8,348.70 | 38.10 | -0.45% |
SSE Composite Index | 3,380.19 | 7.39 | -0.22% |